The EpicOncology™ platform provides detailed epidemiology data for the world’s leading cancer markets. You’ll find comprehensive cancer data sets for these 25 countries in the 2020 data release.
Current and forecasted statistics, flow diagrams, and every data source logged and globally consistent…no other commercially available dataset offers the depth of coverage available in EpicOncology™.
AMERICAS | EUROPE, MIDDLE EAST, AFRICA | ASIA |
United States | France | Japan |
Argentina | Germany | Australia |
Brazil (Urban, Rural) | Italy | China (Urban, Rural, SAR) |
Canada | Spain | India |
Colombia | United Kingdom | South Korea |
Mexico | Denmark | Taiwan |
Finland | ||
Netherlands | ||
Norway | ||
Poland | ||
Russian Federation | ||
Sweden | ||
Turkey |
Note:
Countries in red are new for 2020
SAR = Special Administrative Regions (Hong Kong and Macao)
EpicOncology™ includes detailed cancer data for more than 55 cancer sites and 110+ subtypes and biomarkers. Every cancer site, subtype, and biomarker listed below, you’ll find in EpicOncology‘s data sets.
Cancers | Subsets | Biomarkers |
All Sites | — | — |
Brain | Grade 1 Grade 2 Grade 3 (Anaplastic) Grade 4 (Glioblastoma) |
PTEN |
Breast | HR(+)/HER2(+) HR(+)/HER2(-) HR(-)/HER2(+) HR(-)/HER2(-) |
HR, HER2, BRCA1, BRCA2, PTEN |
Melanoma | — | BRAF, NRAS, PTEN |
Thyroid | Follicular Papillary Medullary Anaplastic Other thyroid |
— |
Cancers | Subsets | Biomarkers |
Biliary Tract | Gallbladder Intrahepatic Cholangiocarcinoma Extrahepatic Cholangiocarcinoma Ampullary Other Biliary |
— |
Colorectal | Colon Rectum |
KRAS, BRAF, dMMR (MSI-H), NRAS, PTEN |
Esophageal | GEJ Adenocarcinoma Non-GEJ Adenocarcinoma Squamous Cell Other Esophageal |
HER2 |
Gastric | GEJ Adenocarcinoma Non-GEJ |
HER2 |
Gastrointestinal Stromal Tumors (GIST) | Gastric Small Intestine Other |
HER2 |
Liver | Hepatocellular (HCC) Other |
— |
Pancreatic | Adenocarcinoma PNET |
PTEN |
Cancers | Subsets | Biomarkers |
Urothelial | Bladder Other Urinary |
— |
Prostate | Hormone Sensitive Castrate Resistant |
PTEN |
Renal Cell | Clear Cell Non-Clear Cell |
— |
Cancers | Subsets | Biomarkers |
Cervical | — | — |
Ovarian | High-Grade Serous (BRCA1) High-Grade Serous (BRCA2) High-Grade Serous (Non-BRCA HRD) High-Grade Serous (Other) Low-Grade Serous Mucinous Endometroid Clear Cell Non-Epithelial |
BRCA1, BRCA2, Non-BRCA HRD, PTEN |
Other Ovarian | Fallopian Tube Primary Peritoneal |
BRCA1, BRCA2, Non-BRCA HRD |
Uterine | — | — |
Cancers | Subsets | Biomarkers |
Larynx Oral Cavity Oropharynx Nasopharynx Hypopharynx Nasal Cavity & Sinus |
Squamous Cell Non-Squamous |
— |
Cancers | Subsets | Biomarkers |
Leukemia, Acute Lymphocytic (ALL) | Ph-Positive Ph-Negative |
— |
Leukemia, Acute Myeloid (AML) | Primary AML Secondary AML Acute Promyelocytic Leukemia (APL) |
IDH, NPM1, FLT3-ITD, CEBPA |
Leukemia, Chronic Lymphocytic (CLL) | — | — |
Leukemia, Chronic Myelogenous (CML) | Chronic Accelerated Blast Crisis |
— |
Lymphoma, Hodgkin’s (HL) | — | — |
Lymphoma, Non-Hodgkin’s (NHL) | Follicular (Gr1/2) Other B-cell Indolent Follicular (Gr3) Mantle Cell Diffuse Large B-cell (DLBCL) Other B-cell Aggressive Cutaneous T-cell (CTCL) Other T-cell Indolent Peripheral T-cell (PTCL) Other T-cell Aggressive |
— |
Multiple Myeloma | Transplant Eligible Transplant Ineligible |
— |
Myelodysplastic Syndromes (MDS) | WHO Subsets IPSS-R |
— |
Myeloproliferative Neoplasms (MPN) | Polycythemia vera (PCV) Essential Thrombocytosis (ET) Myelofibrosis (MF) |
JAK2 |
Cancers | Subsets | Biomarkers |
Lung, Non-Small Cell (NSCLC) |
Adenocarcinoma (EGFR Mutation) Adenocarcinoma (ALK Mutation) Adenocarcinoma (Other) Squamous Cell Large Cell Other |
KRAS, EGFR, ALK, ROS1, BRAF |
Lung, Small Cell (SCLC) |
— | — |
Cancers | Subsets | Biomarkers |
Mesothelioma | — | — |
Osteosarcoma | Osteosarcoma Chondrosarcoma Ewing’s sarcoma Other |
— |
Soft Tissue Sarcoma | Fibrohistiocytoma Liposarcoma Leiomyosarcoma Rhabdomyosarcoma Other |
— |
How does EpicOncology™ present all this data to you? Through three integrated modules that help you query, map out, and analyze it.